A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Фаза 1/2
Завершено
NCT06033261
| Заболевание | Genital Herpes |
|---|
| Фаза | Фаза 1/2 |
|---|
| Спонсор | ModernaTX, Inc. |
|---|
| Статус | Завершено |
|---|
| Участники | 303 участн. |
|---|
| Вмешательство | mRNA-1608, BEXSERO |
|---|
| Дата начала | 6.09.2023 |
|---|
| Дата завершения | 25.04.2025 |
|---|
| Публикация результатов | 8.05.2026 |
|---|
Кратко
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
Number of Participants With Solicited Local and Systemic ARs
Up to Day 64 (Within 7 days after study vaccination) · Participants
| BEXSERO | 74 Participants |
|---|
| mRNA-1608 Dose Level 1 | 75 Participants |
|---|
| mRNA-1608 Dose Level 2 | 75 Participants |
|---|
| mRNA-1608 Dose Level 3 | 74 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs)
Up to Day 85 (Up to 28 days after study vaccination) · Participants
| BEXSERO | 22 Participants |
|---|
| mRNA-1608 Dose Level 1 | 18 Participants |
|---|
| mRNA-1608 Dose Level 2 | 18 Participants |
|---|
| mRNA-1608 Dose Level 3 | 21 Participants |
|---|
Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Study Discontinuation
Day 1 through Day 393 · Participants
| BEXSERO | 0 Participants |
|---|
| mRNA-1608 Dose Level 1 | 2 Participants |
|---|
| mRNA-1608 Dose Level 2 | 2 Participants |
|---|
| mRNA-1608 Dose Level 3 | 2 Participants |
|---|
| BEXSERO | 0 Participants |
|---|
| mRNA-1608 Dose Level 1 | 0 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.